CAMBRIDGE, Mass.--(Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids for the treatment of inflammatory and metabolic diseases, today announced that Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at the following upcoming conferences.)--
“What is coming out of discovery research that shows greatest promise in humans for impacting the progression of type 2 diabetes?”
- Cowen & Company 32nd Annual Health Care Conference, being held March 5-7 at the Boston Marriott Copley Place in Boston. Dr. Jirousek will give a company overview at 8:30 a.m. EST on Monday, March 5.
- Phacilitate’s Metabolic Leaders’ Forum 2012, being held March 12-14 at The Westin San Francisco Market Street in San Francisco. At 10:40 a.m. PST on Monday, March 12, Dr. Jirousek will participate in a presentation and panel discussion titled, “What is the R:B profile you have to strive for with new diabetes drugs to find acceptance not just from the regulator, but also the payer and physician?” At 12:50 p.m. PST, he will present the case study “Rebalancing inflammation in type 2 diabetes: CAT1000 New Chemical Entities” as part of the focus session “What is coming out of discovery research that shows greatest promise in humans for impacting the progression of type 2 diabetes?” At 4:40 p.m. PST, Dr. Jirousek will participate on a panel titled, “CETP inhibitors and beyond: Progress with the search to find more potent drugs to raise HDL.”
- MassBio Annual Meeting, being held March 26-27 at the Royal Sonesta Hotel in Cambridge, Mass. Dr. Jirousek will be a panelist on a break-out panel session at 2:15 p.m. EST on Monday, March 26 titled “Therapeutic Pathways: Diabetes Type II.” The panel will discuss how the age of molecular medicine now shows that many diseases of aging are pathway driven.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that amplify the beneficial effects of omega-3 fatty acids to target the underlying etiologies of a spectrum of complex human diseases. Catabasis’ approach dramatically enhances the therapeutic potential of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), two essential fatty acids found in fish oil, by improving the delivery, potency and efficacy. The company was founded in 2008 and is headquartered in Cambridge, Mass. Please visit www.catabasispharma.com for more information.